Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2024-03-28 00:00:00 ET · period of report 2024-03-26 · accession 0001610717-24-000190 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-28 | 2024-03-26 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $1.57 | +109.8K | 634.2K | +21% | +$172.3K |
| D | 2024-03-28 | 2024-03-26 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $0.00 | -109.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-26 | M | A | 109,768 | $1.57 | 634,249 | D | — | — | (F1) Includes 197,500 restricted stock units. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-03-26 | M | D | 109,768 | $0.00 | 0 | D | $1.57 · — to 2025-02-08 | 109,768 Common Stock | (F4) The Reporting Person previously transferred 9,768 shares subject to this stock option to a family member. (F3) This option is fully vested and exercisable. |